Seeking Alpha

AbbVie drops lawsuit

  • AbbVie's (ABBV +0.4%) spat with Europe's drug regulator ends with the agency's acceptance of redacted documents pertaining to the company's rheumatoid arthritis drug.
  • Last year, the firm sought an injunction to block the medicines regulator from releasing confidential and commercially-sensitive information about the drug.
  • Researchers want access to the raw data as a means to improve third-party scrutiny of new drugs. Unsurprisingly, companies oppose this citing potential damage to their businesses and increased difficulty defending patents.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: